Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 393

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 393
---
 Assets, NetThe components of the Company’s intangible assets were as follows (in thousands, except for weighted-average remaining amortization period): June 30, 2025 Gross Carrying ValueAccumulated Amortization Net Carrying AmountWeighted-Average Remaining Amortization Period (Years)Commercial milestones$59,000 $(9,376)$49,624 12.1Developed technology226,620 (38,751)187,869 10.2Assembled workforce970 (593)377 1.2Total intangible assets$286,590 $(48,720)$237,870 10.6 December 31, 2024 Gross Carrying ValueAccumulated Amortization Net Carrying AmountWeighted-Average Remaining Amortization Period (Years)Commercial milestones$59,000 $(7,092)$51,908 12.6Developed technology226,620 (29,248)197,372 10.7Assembled workforce970 (431)539 1.7Total intangible assets$286,590 $(36,771)$249,819 11.1Amortization expense was $5.9 million and $11.9 million for the three and six months ended June 30, 2025, respectively, and $5.7 million and $11.2 million for the three and six months ended June 30, 2024, respectively. Amortization expense was included in cost of sales in the accompanying unaudited condensed consolidated statements of operations. The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of June 30, 2025 (in thousands): Amount2025 (remaining six months)11,949 202623,791 202723,575 202823,575 202923,575 Thereafter131,405  $237,870 

13

Accrued ExpensesAccrued expenses consist of the following (in thousands): June 30,2025December 31,2024Accrued sales deductions$50,787 $37,361 Accrued compensation and related benefits26,838 32,248 Accrued professional service fees14,023 12,545 Accrued contract manufacturing and non-clinical costs6,540 7,555 Accrued royalties payable11,255 9,361